HC Wainwright Issues Negative Forecast for BCAX Earnings

Bicara Therapeutics Inc. (NASDAQ:BCAX) – Analysts at HC Wainwright decreased their Q2 2026 EPS estimates for shares of Bicara Therapeutics in a research note issued to investors on Monday, June 1st. HC Wainwright analyst R. Burns now anticipates that the company will post earnings per share of ($0.86) for the quarter, down from their prior forecast of ($0.62). HC Wainwright has a “Buy” rating and a $42.00 price target on the stock. The consensus estimate for Bicara Therapeutics’ current full-year earnings is ($3.37) per share. HC Wainwright also issued estimates for Bicara Therapeutics’ Q3 2026 earnings at ($0.89) EPS, Q4 2026 earnings at ($0.92) EPS and FY2026 earnings at ($3.60) EPS.

Bicara Therapeutics (NASDAQ:BCAX) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.93) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.21).

BCAX has been the subject of a number of other research reports. Bank of America started coverage on Bicara Therapeutics in a research report on Wednesday, March 25th. They set a “buy” rating and a $35.00 price objective for the company. Morgan Stanley boosted their target price on Bicara Therapeutics from $36.00 to $37.00 and gave the stock an “overweight” rating in a report on Tuesday, May 12th. Guggenheim began coverage on Bicara Therapeutics in a research note on Monday, May 11th. They issued a “buy” rating and a $42.00 target price on the stock. Wells Fargo & Company raised their price target on Bicara Therapeutics from $11.00 to $16.00 and gave the company an “equal weight” rating in a report on Tuesday, March 31st. Finally, Wedbush reaffirmed an “outperform” rating and issued a $30.00 price target on shares of Bicara Therapeutics in a research report on Tuesday, March 31st. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $30.27.

Bicara Therapeutics Stock Performance

BCAX stock opened at $19.64 on Wednesday. The firm has a 50 day moving average price of $21.43 and a 200-day moving average price of $18.64. Bicara Therapeutics has a 52-week low of $8.48 and a 52-week high of $24.25. The firm has a market capitalization of $1.29 billion, a price-to-earnings ratio of -7.06 and a beta of -0.53.

Insiders Place Their Bets

In other Bicara Therapeutics news, insider David Raben sold 5,500 shares of Bicara Therapeutics stock in a transaction on Monday, April 27th. The stock was sold at an average price of $22.88, for a total value of $125,840.00. Following the completion of the sale, the insider owned 55,286 shares of the company’s stock, valued at approximately $1,264,943.68. This trade represents a 9.05% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Ryan Cohlhepp sold 12,500 shares of Bicara Therapeutics stock in a transaction on Friday, May 15th. The stock was sold at an average price of $20.29, for a total value of $253,625.00. Following the completion of the sale, the chief operating officer directly owned 191,641 shares of the company’s stock, valued at approximately $3,888,395.89. The trade was a 6.12% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 142,969 shares of company stock valued at $2,929,042. 13.80% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Bicara Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. T. Rowe Price Investment Management Inc. grew its stake in shares of Bicara Therapeutics by 596.5% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,236,595 shares of the company’s stock worth $54,472,000 after acquiring an additional 2,771,868 shares during the period. Janus Henderson Group PLC purchased a new stake in Bicara Therapeutics in the fourth quarter worth approximately $44,484,000. Vestal Point Capital LP grew its position in Bicara Therapeutics by 80.6% in the 2nd quarter. Vestal Point Capital LP now owns 5,000,000 shares of the company’s stock worth $46,450,000 after purchasing an additional 2,231,025 shares during the period. Franklin Resources Inc. purchased a new stake in Bicara Therapeutics during the 4th quarter valued at $27,265,000. Finally, State Street Corp lifted its holdings in shares of Bicara Therapeutics by 179.5% during the 4th quarter. State Street Corp now owns 1,649,537 shares of the company’s stock valued at $27,762,000 after buying an additional 1,059,260 shares during the period.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.